Acromegaly: Objectives of Therapy
Untreated acromegaly is associated with increased morbidity and reduced life expectancy [1, 19, 33]. Advances in microsurgical and radiation techniques and the development of new forms of medical treatment have now greatly improved the fate of these patients. On the other hand, refined methods of endocrinological evaluation have shown that complete cure is still not achieved in many patients . New insights into the physiology of GH secretion and its regulation have been gained. More sensitive methods for the radioimmunological determination of GH and the GH-dependent somatomedin-C (Sm-C/IGF I) have made it possible to better define the limits between normal and pathological secretion. This review will therefore attempt to discuss the objectives of treatment especially in terms of GH concentrations and dynamics of secretion following surgical and/or irradiation therapy or during medical treatment.
KeywordsGrowth Hormone Pituitary Adenoma Growth Hormone Concentration Growth Hormone Excess High Growth Hormone
Unable to display preview. Download preview PDF.
- 2.Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action. Life Sci 31: 1133–1140Google Scholar
- 3.Clark RG, Jansson J-O, Isaksson O, Robinson ICAF (1985) Intravenous Growth Hormone: Growth Responses to Patterned Infusions in Hypophysectomized Rats. J Endocrinol 104: 53–61Google Scholar
- 5.Daughaday WH, Starkey RH, Saltman S, Gavin JR III, Mills-Dunlap B, Heath-Monnig E (1987) Characterization of Serum Growth Hormone ( GH) and Insulin-Like Growth Factor I in Active Acromegaly with Minimal Elevation of Serum GH. J Clin Endocrinol Metab 65: 617–623Google Scholar
- 8.Enberg G, Hall K (1984) Immunoreactive IGF-II in Serum of Healthy Subjects and Patients with Growth Hormone Disturbances and Uremia. Acta Endocrinol (Copenh) 107: 164–170Google Scholar
- 13.Hendricks CM, Eastman RC, Takeda S, Asakawa K, Gorden P (1985) Plasma Clearance of Intravenously Administered Pituitary Human Growth Hormone: Gel Filtration Studies of Heterogenous Components. J Clin Endocrinol Metab 60: 864–867Google Scholar
- 21.Quabbe H-J (1978) Endocrinology of Growth Hormone Producing Tumors. In: Fahlbusch R, von Werder K (eds) Treatment of Pituitary Adenomas, First European Workshop on Treatment of Pituitary Adenomas, Rottach-Egern. Thieme, Stuttgart, pp 47–60Google Scholar
- 23.Quabbe H-J (1983) Acromegaly — An Overview. In: Lamberts SWJ, Tilders FJH (eds) Trends in Diagnosis and Treatment of Pituitary Adenomas, Proceedings of the 3rd European Workshop on Pituitary Adenomas, September, AmsterdamGoogle Scholar
- 24.Quabbe H-J (1986) Growth Hormone. In: Lightman SL, Everitt BJ (eds) Neuroendocrinology. Blackwell Scientific Publications, Oxford, pp 409–449Google Scholar
- 32.Winkelmann W (1977) Plasma Growth Hormone Response to TRH, LHRH and Bromocryptine in Patients with Acromegaly. Akromegalie-Studiengruppe der DGE. Acta Endocrinol (Copenh) [Suppl 208] 84: 26 (abstract 24)Google Scholar
- 33.Wright AD, Hill DM, Lowy C, Fraser TR (1970) Mortality in Acromegaly. Q J Med 39:1– 16Google Scholar